Supplement table 1B: Table describing demographics and event frequency in patients that continued or discontinued warfarin during the PT period vs Fiix period.

	PT period (n = 2,363)					Fiix period (n = 1,796)				
	Quit	% of patients quitting	Continue	% of patients continuing	% initial that continue	Quit	% of patients quitting	Continue	% of patients continuing	% of initial that continue
Number	458	100,0	1905	100,0	80,6	344	100,0	1452	100	80,8
Median age	77	-	75	-	-	77	-	75	-	-
Males	249	54,4	1167	61,3	49,4	202	58,7	890	61,3	49,6
Prior:										
Cerebral infarction	66	14,4	290	15,2	12,3	39	11,3	204	14,0	11,4
TIA	36	7,9	115	6,0	4,9	22	6,4	86	5,9	4,8
PAE	2	0,4	12	0,6	0,5	3	0,9	7	0,5	0,4
HTN	133	29,0	531	27,9	22,5	95	27,6	419	28,9	23,3
CHF	138	30,1	391	20,5	16,5	84	24,4	324	22,3	18,0
GFR<60	176	38,4	688	36,1	29,1	152	44,2	567	39,0	31,6
DM	57	12,4	153	8,0	6,5	36	10,5	129	8,9	7,2
Cancer	69	15,1	233	12,2	9,9	60	17,4	183	12,6	10,2
IHD	92	20,1	363	19,1	15,4	79	23,0	256	17,6	14,3
Events during study:										
Major event or any death	61	13,3	59	3.1	2,4	37	10,8	28	1.9	1,5
Event MB	28	6,1	29	1,5	1,2	19	5,5	17	1,2	0,9
Event TE	23	5,0	30	1,6	1,3	7	2,0	11	0,8	0,6
Acute vascular death	13	2,8	0	0,0	0,0	4	1,2	0	0,0	0,0
Fatal TE	9	2,0	0	0,0	0,0	2	0,6	0	0,0	0,0
Non-fatal TE	19	4,1	30	1,6	1,3	5	1,5	11	0,8	0,6
Fatal MB	4	0,9	0	0,0	0,0	2	0,6	0	0,0	0,0
Non-fatal MB	24	5,2	29	1,5	1,2	17	4,9	17	1,2	0,9

Supplement Table 2B

	PT-INR period 12 months	Transition period 6 months	Fiix-NR period 12 months	P-value	Proportional change PT to Fiix period (%)
Number of patients analysed (n)	1,997	1,637	1,437	-	-
Monitoring tests and intervals					
Monitoring tests n (%)	29,018 (100)	11,774 (100)	17,895 (100)	-	
- within range	18,665 (64)	7,607 (65)	11,084 (62)	-	
- below range	5,799 (20)	1,918 (16)	3,430 (19)	-	
- above range	4,544 (16)	2,249 (19)	3,430 (19)	-	
Annual tests per patient	17 (12-24)	17 (12-23)	13 (9-18)	<0.0001	-24
Testing interval in days	20 (15-29)	21 (15-30)	27 (20-39)	<0.0001	+35
Normalized ratios	2.5 (2.3-2.7)	2.6 (2.3-2.8)	2.5 (2.3-2.7)	<0.0001	0
Patient normalized ratio range	1.8 (1.2-2.6)	n.a.	1.6 (1.1-2.3)	<0.0001	-16
Dosing					
Daily dose	4.5 (3.2-6.1)	4.5 (3.2-6.2)	4.4 (3.1-6.1)	0.3823	-2
Patient dose-range	0.71 (0.15-1.57)	n.a.	0.43 (0.00-1.00)	<0.0001	-39
Annual dose adjustments	5.0 (1.1-10.3)	3.2 (0.0-8.8)	3.3 (0.0-7.1)	<0.0001	-34
Dose adjustment interval in days	64 (32-172)	82 (37-137)	95 (46-289)	<0.0001	+48
Time within target range					
Any target range	77 (65-88)	77 (60-96)	79 (67-89)	0.0700	+3
2.5-3.5	70 (53-83)	n.a.	71 (58-82)	0.8518	+1
2-3	77 (65-88)	80 (63-97)	79 (68-89)	0.0005	+3
1.5-2.5	88 (77-98)	n.a.	86 (74-100)	0.7339	-2
Normalized ratio between test variability (variance growth rate)					
All patients – any target	0.15 (0.06-0.30)	0.09 (0.03-0.20)	0.10 (0.04-0.21)	<0.0001	-33
2.5-3.5	0.30 (0.11-0.58)	0.18 (0.07-0.30)	0.15 (0.07-0.36)	0.0009	-50
2-3	0.15 (0.06-0.30)	0.09 (0.03-0.19)	0.10 (0.04-0.20)	<0.0001	-33
1.5-2.5	0.05 (0.03-0.12)	0.05 (0.02-0.08)	0.04 (0.02-0.18)	0.5738	-20

[a]*The 12-month Fiix-NR period was compared to the 6-month transition period and 12-month PT-period. Only patients on maintenance phase anticoagulation (after excluding first 60 days in new patients) are included in the analysis. Patients not showing up for testing for over 90 days were excluded as well as those who had fewer than three tests during the respective period. Results are shown as median (interquartile range) unless otherwise noted. Ranks were compared using the Mann-Whitney test (if two ranks) or Kruskal-Wallis test (if three ranks). N.a. = not applicable (too few tests or dose adjustments during shorter transition period to calculate accurately for the shorter period).*

Supplement Table 3. ICD-10 diagnostic codes searched for clinical event and associated disease assessment:

Hospital charts were searched for the following ICD codes:

Stroke: I63 – I64, I69.3, I69.4

TIA: G45.0 – G45.3, G45.8, G45.9

Hypertension: I10 – I15

Chronic heart failure: I50, I11.0, I13.0, I13.2

Diabetes mellitus: E10 – E14

Renal failure: N17 – N19

Myocardial infarction: I21 – I22, I25.2

Other ischemic heart disease: I25

Vascular disease (V in CHA2DS2-VASc): I21-I22, I25.2, I70 – I71

Cancer: C10 – C97

Peripheral arterial embolism: I74

Venous thromboembolism: I26.0, I26.9, I63.6, I67.6, I80 – I82

Gastrointestinal bleeding: I85.0, I98.3, K25.0, K25.2, K25.4, K25.6,K26.0, K26.2, K26.4, K26.6, K27.0, K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K62.5, K92.0 – K92.2, K29.0,

Intracranial bleeding: I60 – I62, S06.4 – S06.8.

Other bleeding/anemia: D62, R58, D50.0, D50.8, D50.9, H35.6, N02, N93.8, N93.9, R31, R04.0, Y44.2, T81.0, D68.3, T45.5, I23.0, I31.2, J94.2, H43.10, H43.11, H43.12, H43.13, H11.3, G95.19.